Dianthus Therapeutics DNTH Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's total equity?
- Dianthus Therapeutics (DNTH) reported total equity of $1.2B in Q1 2026.
- How has Dianthus Therapeutics's total equity changed year-over-year?
- Dianthus Therapeutics's total equity increased by 265.6% year-over-year, from $328.61M to $1.2B.
- What is the long-term trend for Dianthus Therapeutics's total equity?
- Over 5 years (2020 to 2025), Dianthus Therapeutics's total equity has grown at a 27.9% compound annual growth rate (CAGR), from $143.91M to $493.4M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.